FTSE 100 : GSK boosts the LSE as it swallows a $2.2bn pill

GSK’s shares leapt by more than 6% after the company agreed to shell out up to $2.2 billion to resolve most of the lawsuits in the U.S. concerning its heartburn drug, Zantac. This settlement, involving deals with 10 plaintiff firms representing about 80,000 claimants, is set to be fully wrapped up b…
© MarketScreener.com 2024